Electrical Nerve Stimulation Shows Promise for Severe Breathing Difficulty in COPD

Dyspnea—the distressing sensation of breathlessness—affects 10% of the general population and represents one of the most challenging symptoms in chronic obstructive pulmonary disease (COPD). In severe COPD, 90% of patients experience dyspnea in their final year, with nearly half finding no relief from current treatments including opioids, ventilatory support, and pulmonary rehabilitation.

Canadian researchers are pioneering the first clinical trial investigating whether non-invasive electrical nerve stimulation can alleviate dyspnea perception. The feasibility study at the University of Sherbrooke tests two neuromodulation approaches: transcutaneous vagus nerve stimulation (tVNS) targeting respiratory pathways, and trigeminal transcutaneous electrical nerve stimulation (TENS) based on the gate control theory used in pain management.

The crossover trial enrolls eight severe COPD patients who undergo submaximal exercise testing while receiving either active stimulation or sham treatment. Participants perform constant work rate exercise at 80% of their VO2 max while researchers measure dyspnea using standardized scales including the Borg scale and Visual Analogue Scale.

The rationale builds on neuromodulation's proven success in treating epilepsy, chronic pain, and movement disorders. Since dyspnea arises from complex neurological pathways involving mismatched ventilatory signals, targeted electrical stimulation could modulate these pathways without completely suppressing the body's important alarm signals.

While this is only a feasibility study with a small sample size, it represents a crucial first step toward developing new treatments for a symptom that drives some patients to consider medical assistance in dying. The non-invasive nature makes these approaches potentially safer and more accessible than current options, offering hope for the millions suffering from severe breathlessness.